| Identification | Back Directory | [Name]
ABT-263-piperazine | [CAS]
2143096-93-7 | [Synonyms]
ABT-263-piperazine
Navitoclax-piperazine
Navitoclaxpiperazine,Bcl-2 Family,B-cell,VHL,Target Protein-binding Moiety,inhibit,Inhibitor,lymphoma,ubiquitin,Ligands for Target Protein for PROTAC,Navitoclax-piperazine,ligase,Navitoclax piperazine
Benzamide, 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-1-[(phenylthio)methyl]-3-(1-piperazinyl)propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]- | [Molecular Formula]
C47H56ClF3N6O5S3 | [MDL Number]
MFCD32693949 | [MOL File]
2143096-93-7.mol | [Molecular Weight]
973.63 |
| Hazard Information | Back Directory | [Uses]
Navitoclax-piperazine is a Navitoclax analog. Navitoclax is a BCL-XL inhibitor. Navitoclax can be used as a target protein ligand (Ligands for Target Protein for PROTAC) to develop and design PROTAC BCL-XL degraders with anti-tumor activity. Navitoclax can be used in the synthesis of PROTAC DT2216 (HY-130604)[1]. | [IC 50]
Bcl-xL | [References]
[1] Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938–1947 (2019). |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|